DCGI approves Covovax for 12 to 17-year-olds

Tribune Web Desk

Updated At : 11:33 AM Mar 10, 2022 IST

Unlock Exclusive Insights with The Tribune Premium

Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits

Yearly Premium ₹999 ₹349/Year

Yearly Premium $49 $24.99/Year

New Delhi, March 9

The national drug regulator on Wednesday granted emergency use approval to Covovax, the anti-Covid shot of Serum Institute of India, for use in 12 to 17-year-olds.

The approval follows a recommendation to this effect by the Drugs Controller General of India’s (DCGI) subject expert committee on Covid. Covovax was earlier authorised for use in adults. It is, however, not part of the national inoculation drive.

Covovax is the fourth vaccine candidate to receive the regulator’s nod in children under 18. Currently, India is not inoculating children under 15 years of age. The ongoing children’s vaccination drive is using the two-dose Covaxin to cover 15 to 18-year-olds. — TNS

Other jabs for children

Corbevax by Biological E
ZyCov-D by Zydus Cadila
Covaxin by Bharat Biotech

*These jabs are approved for kids above 12 years old

The Tribune, now published from Chandigarh, started publication on February 2, 1881, in Lahore (now in Pakistan). It was started by Sardar Dyal Singh Majithia, a public-spirited philanthropist, and is run by a trust comprising five eminent persons as trustees.

The Tribune, the largest selling English daily in North India, publishes news and views without any bias or prejudice of any kind. Restraint and moderation, rather than agitational language and partisanship, are the hallmarks of the newspaper. It is an independent newspaper in the real sense of the term.

The Tribune has two sister publications, Punjabi Tribune (in Punjabi) and Dainik Tribune (in Hindi).

Remembering Sardar Dyal Singh Majithia

Designed and developed by : SORTD

Unlock Exclusive Insights with The Tribune Premium

Suggested Articles